Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Blood (2021) 138 (Supplement 1): 236.

https://doi.org/10.1182/blood-2021-145116

Published: 2021

Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-135872

Published: 2020

Journal Articles

Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Marie Lindgren, Erik Ahlstrand, MD PhD, Helna Pettersson, MD, Maria Liljeholm, Anna Ravn-Landtblom, MD, Stefan Scheding, Prof, Björn Andréasson, MD PhD, Jan Samuelsson, MD PhD

Blood (2019) 134 (Supplement_1): 1658.

https://doi.org/10.1182/blood-2019-124374

Published: 2019

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Blood (2018) 132 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2018-99-111559

Published: 2018

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison Scotch, MD MPH, Robyn M. Scherber, MD, Marlene Bruso, MS, Heidi Elizabeth Kosiorek, MS, Amylou C. Dueck, PhD, Holly Geyer, MD, Veena D. S. Fauble, MD, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, PhD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, David M Ross, MBBS, PhD FRACP, FRCPA, Federico Sackman, MD PhD, Jean-Loup Demory, MD PhD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Jan J. Michiels, PhD, Deepti Radia, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Frances Wadelin, MD, Robert N. Lown, MBBS, MRCP, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Wunna Swe, Jonathan O. Cullis, MD, Nigel Sargant, BSc, FRPATH, MRCP,, Paul Moreton, MD MRCP, FRCPath, Catherine Cargo, MB, FRCPath, Mallika Sekhar, MBBS, MD FRCPath, FRCP, Satareh Shekouhi, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 1641.

https://doi.org/10.1182/blood.V130.Suppl_1.1641.1641

Published: 2017

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison H Scotch, MD MPH, Robyn M. Scherber, MD MPH, Nan Zhang, MS, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Holly Geyer, MD, Veena Fauble, MD, Alessandro M. Vannucchi, MD PhD, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, MD PhD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, David M. Ross, MBBS, PhD FRACP, FRCPA, Federico Sackmann, MD, Jean-Loup Demory, MD, Constantine S. Tam, Jan J. Michiels, PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Mohan Mahalakshmi, MD, Daniel Jennings, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Frances Wadelin, MD, Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Victoria Drew, John Hudson, Mary Frances McMullin, MD, Wunna Swe, Jonathan O. Cullis, MD MB, BS, MA, FRCP, FRCPath, Nigel Sargant, BSc, FRPATH, MRCP,, Paul Moreton, MD MRCP, MRCPath, Mari Frances Kilner, MBBS,MRCP,FRCPath, Catherine Cargo, MB, FRCPath, Mallika Sekhar, MBBS,MDFRCPath,FRCP, Satareh Shekouhi, Ruben A. Mesa, MD

Blood (2016) 128 (22): 5479.

https://doi.org/10.1182/blood.V128.22.5479.5479

Published: 2016

Journal Articles

Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Bjorn Andreasson, Maria Ferrari, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Keith Cannon, MD, Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 5463.

https://doi.org/10.1182/blood.V128.22.5463.5463

Published: 2016

Journal Articles

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, MD, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Bjorn Andreasson, Maria Ferarri, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Gunnar Birgegard, MD PhD, Keith Cannon, MD, Xuijuan Sun, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 3117.

https://doi.org/10.1182/blood.V128.22.3117.3117

Published: 2016

Journal Articles

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

Barbara Gamberi, Miguel Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, Roman Hájek, Monique Minnema, Meletios A Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, MD PhD, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonia Di Micco, Pamela Bacon, Igor Blau

Blood (2016) 128 (22): 3331.

https://doi.org/10.1182/blood.V128.22.3331.3331

Published: 2016

Journal Articles

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Blood (2015) 126 (23): 1602.

https://doi.org/10.1182/blood.V126.23.1602.1602

Published: 2015

Journal Articles

Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

Holly Geyer, MD, Robyn M. Scherber, MD MPH, Heidi Kosiorek, M.S., Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Zhijian Xiao, DO, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Döhner, MD, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, MD, Dana Ranta, Lydia Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yu Zhang, B.S., Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter A. te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 5175.

https://doi.org/10.1182/blood.V126.23.5175.5175

Published: 2015

Journal Articles

A Population-Based Study of Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012

Malin Hultcrantz, MDPhD, Therese M-L Andersson, MSc PhD, Ola Landgren, MD PhD, Paul W Dickman, MSc PhD, Bjorn Andreasson, MDPhD, Magnus Bjorkholm, MD PhD, Sigurdur Y Kristinsson, MD PhD

Blood (2015) 126 (23): 1605.

https://doi.org/10.1182/blood.V126.23.1605.1605

Published: 2015

Journal Articles

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Claire N. Harrison, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Zhijian Xiao, DO, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Döhner, MD, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, Dana Ranta, Jean Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yu Zhang, B.S., Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter A. te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 4073.

https://doi.org/10.1182/blood.V126.23.4073.4073

Published: 2015

Journal Articles

Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

Holly Geyer, MD, Robyn M Scherber, MD MPH, Heidi Kosiorek, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Zhijian Xiao, MD, Stefanie Slot, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Dohner, MD, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, MD, Dana Ranta, Lydia Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yue Zhang, MD, Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 4080.

https://doi.org/10.1182/blood.V126.23.4080.4080

Published: 2015

Journal Articles

Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients

Holly Lynn Geyer, MD, Robyn M Scherber, MD MPH, Amylou Constance Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Zhijian Xiao, MD, Stephanie Slot, BSc, Sonja Zweegman, MDPhD, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, MD PhD, Konstanze Dohner, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti H Radia, MDFRCPath MSc MDEd, Pablo J. Muxi, MD, Federico Sackman, Carlos Besses, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Gunnar Birgegard, Karin Bonatz, MD, Andreas Reiter, MD, Françoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, MD, Keith Cannon, MD, Peter te Boekhorst, MD PhD, Harry C Schouten, MDPhD, Heike L. Pahl, PhD, Martin Griesshammer, Frank Stegelmann, MD, Thomas Lehmann, MD, Zefeng Xu, MD, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Ruben Mesa, MD

Blood (2014) 124 (21): 1848.

https://doi.org/10.1182/blood.V124.21.1848.1848

Published: 2014

Journal Articles

Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study)

Tiziano Barbui, MD, Arianna Masciulli, MSc, PhD, Marco Scarano, Sc.D., Gianni Tognoni, Sara Sisti, Alessandra Di Lelio, Alessandro M. Vannucchi, MD, Mario Cazzola, MD, Alessandro Rambaldi, Konstanze Doehener, Francisco Cervantes, MD PhD, Francesco Passamonti, MD, Andreas Reiter, MD, Steffen Koschmieder, MD, Dietger Niederwieser, MD, Bjorn Andreasson, MD, Peter L. Johansson, MD PhD, Andreas Hochhaus, MD, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 1849.

https://doi.org/10.1182/blood.V124.21.1849.1849

Published: 2014

Journal Articles

A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

Marie Lindgren, MD, Jan Samuelsson, MD PhD, Lars Nilsson, MD PhD, Håvar Knutsen, MD, Waleed Ghanima, MDPhD, Maria Åström, MD PhD, Elisabeth Ejerblad, MD, Anna Hugosson, MD, Peter L. Johansson, MD PhD, Björn Andréasson, MD PhD

Blood (2014) 124 (21): 1861.

https://doi.org/10.1182/blood.V124.21.1861.1861

Published: 2014

Journal Articles

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Blood (2014) 124 (7): 1183–1191.

https://doi.org/10.1182/blood-2014-04-572545

Published: 2014

Journal Articles

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Blood (2014) 123 (24): 3803–3810.

https://doi.org/10.1182/blood-2013-09-527903

Published: 2014

Includes: Supplemental data

Journal Articles

Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response

Robyn M. Emanuel, MD, MPH, Amylou Constance Dueck, PhD, Holly Lynn Geyer, MD, Jean-Jacques Kiladjian, MD, PhD, Stephanie Slot, BSc, Sonja Zweegman, MD PhD, Peter te Boekhorst, MD, PhD, Suzan Commandeur, PhD, Harry C. Schouten, MD, PhD, Federico Sackmann, MD, Dolores Hernandez, MD, Ana Kerguelen Fuentes, Heike L. Pahl, PhD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, MD, Karin Bonatz, MD, Andreas Reiter, MD, Françoise Boyer, Gabriel Etienne, MD, PHD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, PhD, Claire N Harrison, DM, FRCP, FRCPath, Deepti H Radia, MD FRCPath MSc Med Ed, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD, PhD, Francisco Cervantes, MD, PhD, Peter Johansson, MD, PhD, Tiziano Barbui, MD, Giovanni Barosi, MD, Alessandro M Vannucchi, MD, Francesco Passamonti, MD, Bjorn Andreasson, MD, Maria Ferrari, MD, Martin Griesshammer, MD, PhD, Alessandro Rambaldi, MD, Jan Samuelsson, MD, Gunnar Birgegard, MD, PhD, Zhijian Xiao, MD, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Robert Peter Gale, MD, PhD, DSc, FACP, Ayalew Tefferi, MD, Ruben A. Mesa, MD

Blood (2013) 122 (21): 4067.

https://doi.org/10.1182/blood.V122.21.4067.4067

Published: 2013

NARROW

The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib

A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr -Mutated Low Risk Essential Thrombocythemia

Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

A Population-Based Study of Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients

Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study)

A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only